Real-time Automated Program for IDentification of VT Origin

  • STATUS
    Recruiting
  • End date
    May 1, 2022
  • participants needed
    8
  • sponsor
    Amir AbdelWahab
Updated on 3 February 2021
electrocardiogram
myocardial infarction
infarct
shock
amiodarone
catheter ablation
antiarrhythmic drug
cardioversion
sustained ventricular tachycardia

Summary

RAPID-VT Pilot is a single centre prospective cohort pilot study to assess the feasibility, safety and efficacy of catheter ablation of ventricular tachycardia (VT) guided by a novel real-time software to localize the origin of VT during the ablation procedure.

Description

Consecutive patients with ischemic heart disease and clinical indication of VT ablation will undergo baseline clinical evaluation, echocardiography and cardiac CT imaging using a contrast-enhanced cardiac-gated method with a 64-section scanner. Trans-axial CT images comprising the whole heart volume will be exported in DICOM format. CT image processing will be performed and will be used to delineate the LV endocardial and/or epicardial geometries. These data will be imported into the RAPID-VT software and the 3D-electranatomical mapping system for image integration.

During the VT ablation procedure, VT(s) induction will be performed. The VT(s) 12-lead ECG will be acquired by the RAPID-VT software and will be localized to the scar margin using the RAPID-VT software. Catheter ablation will be attempted at software-determined sites.

Post procedure, patient will be followed up for a minimum of 6 months. That will include Remote ICD follow-up and telephone study visits. Follow-up at 6 months will include a clinic visit for assessment of heart failure status, ECG, ICD interrogation and changes in antiarrhythmic drug therapy.

Details
Condition Vascular Diseases, Heart disease, Tachycardia, Ventricular tachycardia, Ischemic Heart Disease, Fast Heart Rate (Tachycardia), Cardiac Ischemia, Myocardial Ischemia, Cardiac Disease
Treatment RAPID-VT Software guided ablation
Clinical Study IdentifierNCT03523286
SponsorAmir AbdelWahab
Last Modified on3 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients will be eligible for inclusion if they fulfilled VANISH inclusion criteria by having both of
Prior myocardial infarction (pathological Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause)38 and
One of the following VT events within the last 6 months while on Amiodarone or another class III or class I antiarrhythmic drug
Sustained monomorphic VT documented on 12-lead ECG or rhythm strip requiring termination by pharmacologic means or DC cardioversion, B: 3 episodes of symptomatic VT treated with anti-tachycardia pacing (ATP), C: 1 appropriate ICD shocks, D: 3 VT episodes within 24 hours, separated by 5 minutes, E: sustained VT below detection rate of an ICD

Exclusion Criteria

Patients will be excluded from the trial if they
Are unable or unwilling to provide informed consent
Have active ischemia or another reversible cause of VT (e.g. drug-induced arrhythmia), or had recent acute coronary syndrome requiring revascularization
Are antiarrhythmic drug-nave
Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves
Have had a prior catheter ablation procedure for VT
Are in renal failure (Creatinine clearance <15 mL/min)
Have NYHA Functional class IV heart failure or CCS Functional class IV angina
Have had recent ST elevation myocardial infarction (< 1 month)
Are pregnant or have a systemic illness likely to limit survival to <1 year
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note